A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910